Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors
The ovary and the endometrium are hormone dependent organs. Receptors for different sex
hormones are found commonly in epithelial ovarian and endometrial cancers. LHRH and its
receptors are expressed in about 80% of human ovarian and endometrial cancers. As binding
sites are present on tumors in higher concentrations than on most normal tissues, these
receptors represent a specific target for AEZS-108 in which doxorubicin is coupled to an
Patients whose tumor specimen have shown to be positive for LHRH receptor expression will be
investigated for tumor response and tolerability.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor response as per RECIST or (for Ovarian CA patients without evaluable target lesion following RECIST) GCIG criteria
up to six 3-weekly treatment cycles
Günter Emons, Prof.Dr.med.
Universitäts-Frauenklinik / Department of Obstetrics and Gynecology, University of Göttingen
Germany: Federal Institute for Drugs and Medical Devices